OTCMKTS:RHHBY

Roche Holding Ag Stock News

Healthcare > Drug Manufacturers - General

Buy RHHBY

*Your capital is at risk

$51.57

+2.51 (+5.12%)

At Close: Jun 04, 2026

Bear market is coming in 2025, warns David Roche, but the Fed will step in before it turns 'draconian'

01:17am, Monday, 12'th Aug 2024

Veteran investor David Roche expects a bear market in 2025, caused by smaller-than-expected rate cuts, a slowing U.S. economy and an AI bubble. Those factors could cause a bear market of minus 20% in

Roche considering divesting $1.9 bln cancer data startup, FT reports

12:16am, Wednesday, 07'th Aug 2024

Swiss pharmaceutical company Roche is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.

07:30am, Friday, 02'nd Aug 2024

The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight l

European Commission approves Roche's Vabysmo for treatment of retinal vein occlusion (RVO)

01:00am, Tuesday, 30'th Jul 2024

Basel, 30 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved Vabysmo® (faricimab) for the treatment of visual impairment due to macular edem

Roche ‘fast-tracking' weight-loss drug that rivals Wegovy

02:31pm, Monday, 29'th Jul 2024

Pharmaceutical giant Roche is "fast-tracking" its own weight-loss pills in clinical trials as it looks to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data

08:29am, Monday, 29'th Jul 2024

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candida

Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?

07:30am, Monday, 29'th Jul 2024

Roche just reported some solid data with its weight loss pill program. Competitors might have a problem on the horizon as a result.

Roche closes acquisition of LumiraDx's Point of Care technology to expand access to diagnostic testing in primary care

01:00am, Monday, 29'th Jul 2024

Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx's Point of Care technology, following the receipt of all required antitrust and r

Roche to fast-track weight loss pill to compete with rivals, FT reports

12:15am, Monday, 29'th Jul 2024

Swiss pharmaceutical company Roche plans to fast-track its anti-obesity drugs to challenge Eli Lilly and Novo Nordisk after unveiling promising data for a weight-loss pill, the Financial Times reporte

Will Western Union's (WU) Q2 Profits Wire Up or Break Down?

12:10pm, Thursday, 25'th Jul 2024

Western Union's (WU) second-quarter results are likely to reflect a decline in CMT transactions.

Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised

11:08am, Thursday, 25'th Jul 2024

Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.

Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo

09:00am, Thursday, 25'th Jul 2024

Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry. Attendees can experience firsthand how fully integrated systems and

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by